As demand for services rises and money pours into the field, behavioral healthcare providers need to stick to good principles and keep the needs of patients top of mind, Zac Clark, co-founder of Release Recovery, told TCIV attendees in a...
As demand for services rises and money pours into the field, behavioral healthcare providers need to stick to good principles and keep the needs of patients top of mind, Zac Clark, co-founder of Release Recovery, told TCIV attendees in a...
Charles Raison, MD, discusses the history, pharmacology, and clinical potential of the lesser-known psychedelics, including Ibogain, 5-MeO-DMT, LSD, and DMT.
Charles Raison, MD, discusses the history, pharmacology, and clinical potential of the lesser-known psychedelics, including Ibogain, 5-MeO-DMT, LSD, and DMT.
The US Food and Drug Administration has approved Adlarity® (donepezil transdermal system) for release in the fall of 2022. Adlarity is indicated in the treatment of adults with Alzeheimer-type mild to severe dementia symptoms.
Adlarity is...
The US Food and Drug Administration has approved Adlarity® (donepezil transdermal system) for release in the fall of 2022. Adlarity is indicated in the treatment of adults with Alzeheimer-type mild to severe dementia symptoms.
Adlarity is...
Jane Sanville, MPH, a senior policy analyst for the Office of National Drug Control Policy, discusses the importance of drug use prevention initiatives for adolescents, as well as steps that schools and communities can take to address the...
Jane Sanville, MPH, a senior policy analyst for the Office of National Drug Control Policy, discusses the importance of drug use prevention initiatives for adolescents, as well as steps that schools and communities can take to address the...
